MD871Z - Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы - Google Patents
Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы Download PDFInfo
- Publication number
- MD871Z MD871Z MDS20140054A MDS20140054A MD871Z MD 871 Z MD871 Z MD 871Z MD S20140054 A MDS20140054 A MD S20140054A MD S20140054 A MDS20140054 A MD S20140054A MD 871 Z MD871 Z MD 871Z
- Authority
- MD
- Moldova
- Prior art keywords
- breast cancer
- radiotherapy
- patients
- chemotherapy
- complications
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 32
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 32
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 18
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002113 nanodiamond Substances 0.000 claims abstract description 16
- 235000012054 meals Nutrition 0.000 claims abstract description 11
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 239000010476 amaranth oil Substances 0.000 claims abstract description 9
- 239000004359 castor oil Substances 0.000 claims abstract description 9
- 235000019438 castor oil Nutrition 0.000 claims abstract description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 9
- 240000001592 Amaranthus caudatus Species 0.000 claims abstract description 8
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims abstract description 8
- 235000012735 amaranth Nutrition 0.000 claims abstract description 8
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 238000001802 infusion Methods 0.000 claims description 8
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 6
- 240000000785 Tagetes erecta Species 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract 1
- 235000003880 Calendula Nutrition 0.000 abstract 1
- 240000001432 Calendula officinalis Species 0.000 abstract 1
- 229940098465 tincture Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 12
- 241000245665 Taraxacum Species 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000736851 Tagetes Species 0.000 description 3
- 235000012308 Tagetes Nutrition 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000035346 Margins of Excision Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000033206 Early menarche Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000009923 canephron Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к онкологии и может быть использовано для профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы.Согласно изобретению, заявленный метод состоит в том, что приминают 200 мл смеси на основе настойки корней одуванчика и растительной части календулы, взятые в соотношение 1:1 и наноалмазы 4…10 нм, в концентрации 10-9…10-10 г/л, per os, два раза в день за 20 мин до еды, одновременно один раз в день приминают 20 мл смеси на основе амарантового и касторового масла, взятые в соотношение 1:1 и наноалмазы 4…10 нм, в концентрации 10-9…10-10 г/л, per os, за 20 мин до еды, за 5 дней до курса радиотерапии или химиотерапии, курс лечения составляет 20…25 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140054A MD871Z (ru) | 2014-04-18 | 2014-04-18 | Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140054A MD871Z (ru) | 2014-04-18 | 2014-04-18 | Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD871Y MD871Y (ru) | 2015-01-31 |
| MD871Z true MD871Z (ru) | 2015-09-30 |
Family
ID=52440959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20140054A MD871Z (ru) | 2014-04-18 | 2014-04-18 | Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD871Z (ru) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| RU2197977C2 (ru) * | 2001-04-17 | 2003-02-10 | Дмитриенко Николай Васильевич | Масло семян тыквы, обладающее противовоспалительным, противоязвенным и гепатопротекторным действием, и способ его получения |
| EA201001000A1 (ru) * | 2010-04-19 | 2011-10-31 | Алмагуль Тулеуовна Маншарипова | Антиоксидантное средство масляный бальзам "ювелакс" |
-
2014
- 2014-04-18 MD MDS20140054A patent/MD871Z/ru not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| RU2197977C2 (ru) * | 2001-04-17 | 2003-02-10 | Дмитриенко Николай Васильевич | Масло семян тыквы, обладающее противовоспалительным, противоязвенным и гепатопротекторным действием, и способ его получения |
| EA201001000A1 (ru) * | 2010-04-19 | 2011-10-31 | Алмагуль Тулеуовна Маншарипова | Антиоксидантное средство масляный бальзам "ювелакс" |
Non-Patent Citations (2)
| Title |
|---|
| Каприн А.Д., Семин А.В., Костин А.А. Эффективность препарата "Канефрон Н" у онкологически больных получающих лучевую терапию на органы малого таза. Человек и лекарство, №5, том 15, 2007 * |
| Ролик И.С. Биологические препараты в реабилитации больных раком: руководство для врачей. Москва, Арнебия, 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD871Y (ru) | 2015-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Azeez et al. | New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling | |
| Russo et al. | Toward a physiological approach to breast cancer prevention. | |
| Chandanos et al. | Oestrogen and the enigmatic male predominance of gastric cancer | |
| Berclaz et al. | Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast | |
| Hsu et al. | The effects of isoliquiritigenin on endometriosis in vivo and in vitro study | |
| Rajoria et al. | Estrogen activity as a preventive and therapeutic target in thyroid cancer | |
| Muñoz et al. | Ovarian stimulation in patients with breast cancer | |
| Jordan et al. | Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer | |
| Gadducci et al. | Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data | |
| US11110101B2 (en) | Prostate function support formula | |
| MD871Z (ru) | Метод профилактики осложнений радиотерапии или химиотерапии у пациентов с раком молочной железы | |
| Wang et al. | Qingchang mixture prevents the intestinal ischemia-reperfusion injury through tlr4/nf-kb pathway | |
| Lazzeroni et al. | The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it | |
| Ansari et al. | Chemoprevention of carcinoma prostate. A review | |
| Septiani et al. | Role of the red fruit (Pandanus conoideus Lam) ethyl acetate fraction on the induction of apoptosis vs. downregulation of survival signaling pathways in cervical cancer cells | |
| CN104587140B (zh) | 藜芦雌激素受体拮抗剂样新作用 | |
| de Carvalho et al. | First pregnancy and live birth from ex vivo-retrieved metaphase II oocytes from a woman with bilateral ovarian carcinoma: a case report | |
| Nwonuma et al. | Uterine fibroid: risk factors and therapeutic interventions | |
| Sruthi et al. | Role of Vitamin D in Gynecological Cancer: State of the Art | |
| Almalki | The Effects of Wild Yam Root (Dioscorea villosa) Extract in Human Triple Negative MDA-MB-231 Breast Cancer Cells | |
| Schwöbel et al. | Surgical treatment of ovarian tumors in childhood | |
| Sharma et al. | Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer | |
| Vatavu et al. | BREAST ABNORMALITIES AND CONGENITAL ANOMALIES. | |
| Patil et al. | Breast Cancer: Estradiol-Progesterone Balance Paradigm | |
| WO2019024249A1 (zh) | 治疗卵巢早衰的胎盘提取物生物凝胶制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |